Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of ARCoV mRNA Vaccine for COVID-19 in Adults
NCT04847102Phase 3Unknown
- Sponsor
- Walvax Biotechnology Co., Ltd.
- Start
- Jul 2021
- Primary completion
- Nov 2021
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
- Countries
- 2
01
Overview
A Phase 3 trial of ARCoV in coronavirus disease 2019 (COVID-19), sponsored by Walvax Biotechnology Co., Ltd.. Status: unknown.
02
Drugs
ARCoV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04847102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04847102.